Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan.
Cell Transplant. 2012;21(5):997-1009. doi: 10.3727/096368911X603611. Epub 2011 Oct 14.
Depletion of pancreatic β-cells results in insulin insufficiency and diabetes mellitus (DM). Single transplantation of mesenchymal stem cells exhibits short-term effects in some preclinical studies. Here, we further investigated the long-term therapeutic effects of multiple intravenous MSC transplantations. In this study, multiple human MSC transplantations (4.2 × 10(7) cells/kg each time) were performed intravenously at 2-week intervals into streptozocin (STZ)-induced diabetic mice for 6 months. Blood sugar, insulin, renal function, cholesterol, and triglyceride levels were monitored. We demonstrated that compared to single intravenous transplantation, which only transiently decreased hyperglycemia, multiple MSC transplantations effectively restored blood glucose homeostasis. Systemic oxidative stress levels were reduced from the seventh week of treatment. From the 11th week, production of human insulin was markedly increased. When MSC transplantation was skipped after blood sugar level returned to normal at the end of 15th week, a sharp rebound of blood sugar occurred, and was then controlled by subsequent transplantations. At the end of 6 months, histopathology examination revealed MSCs specifically engrafted into liver tissues of the recipients. Fifty-one percent of human cells in the recipient liver coexpressed human insulin, especially those surrounding the central veins. Taken together, intravenous MSC delivery was safe and effective for blood glucose stabilization in this preclinical DM model. Multiple transplantations were essential to restore and maintain glucose homeostasis through decreasing systemic oxidative stress in the early stage and insulin production in the late stage. Liver engraftment and differentiation into insulin-producing cells account for the long-term therapeutic effects of MSCs.
胰岛 β 细胞耗竭可导致胰岛素不足和糖尿病(DM)。间充质干细胞(MSC)的单次移植在一些临床前研究中表现出短期效果。在这里,我们进一步研究了多次静脉 MSC 移植的长期治疗效果。在这项研究中,我们在 6 个月内每隔 2 周通过静脉内给予 STZ 诱导的糖尿病小鼠 4.2×10(7)个细胞/kg 的多次人 MSC 移植。监测血糖、胰岛素、肾功能、胆固醇和甘油三酯水平。我们证明,与仅短暂降低高血糖的单次静脉内移植相比,多次 MSC 移植有效地恢复了血糖稳态。从治疗的第 7 周开始,全身氧化应激水平降低。从第 11 周开始,人胰岛素的产生明显增加。当第 15 周末血糖水平恢复正常后跳过 MSC 移植时,血糖会急剧反弹,随后通过后续移植得到控制。在 6 个月结束时,组织病理学检查显示 MSC 特异性地植入到受者的肝组织中。受者肝脏中 51%的人细胞共表达人胰岛素,特别是那些围绕中央静脉的细胞。总之,静脉内 MSC 传递在该临床前 DM 模型中对于血糖稳定是安全有效的。多次移植对于通过早期降低全身氧化应激和晚期产生胰岛素来恢复和维持葡萄糖稳态是必要的。肝定植和分化为胰岛素分泌细胞是 MSC 长期治疗效果的原因。